The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Natural history of multiple sclerosis: a unifying concept
Abstract
Multiple sclerosis can follow very different patterns of evolution and variable rates of disability accumulation. This raises the issue whether it represents one or several distinct diseases. We assessed demographic and clinical characteristics in 1844 patients with multiple sclerosis that we categorized according to the classification of Lublin and Reingold (1996) into 1066 (58%) relapsing-remitting, 496 (27%) secondary progressive, 109 (6%) progressive relapsing and 173 (9%) primary progressive cases of multiple sclerosis. Relapsing-remitting and secondary progressive cases shared similar age at disease onset (median = 28.7 versus 29.5 years; P = 0.21), initial symptoms of the relapsing-remitting phase, degree of recovery from the first neurological episode, and time from the first to the second episode. By contrast, disease duration was twice as long in secondary progressive than in relapsing-remitting cases (mean +/- SD = 17.6 +/- 9.6 versus 8.7 +/- 8.6 years; P < 0.001). Progressive relapsing and primary progressive cases were essentially similar in their clinical characteristics. In patients experiencing a progressive course, median age at onset of progressive phase was similar in secondary progressive cases and in cases who were progressive from onset (39.1 versus 40.1 years; P = 0.47). The proportion of cases with superimposed relapses during progression was approximately 40% in both categories. Finally, the 1562 patients with an exacerbating-remitting initial course and the 282 patients with a progressive initial course of the disease were essentially similar with respect to the time course of disability accumulation from assignment to a given disability score, and the age at assignment of disability landmarks. These observational data suggest that the clinical phenotype and course of multiple sclerosis are age dependent. Relapsing-remitting disease can be regarded as multiple sclerosis in which insufficient time has elapsed for the conversion to secondary progression; secondary progressive forms as relapsing-remitting multiple sclerosis that has 'grown older'; and progressive from onset cases as multiple sclerosis 'amputated' from the usual preceding relapsing-remitting phase. Times to reach disability milestones, and ages at which these landmarks are reached, follow a predefined schedule not obviously influenced by relapses, whenever they may occur, or by the initial course of the disease, whatever its phenotype. This leads to a unifying concept of the disease in which primary and secondary progression might be regarded as essentially similar. From the clinical and statistical positions, multiple sclerosis might be considered as one disease with different clinical phenotypes rather than an entity encompassing several distinct diseases-the position of complexity rather than true heterogeneity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
Schumacher, G. A., Beebe, G., Kibler, R. F., Kurland, L. T., Kurtzke, J. F., McDowell, F., Nagler, B., Sibley, W. A., Tourtellotte, W. W., & Willmon, T. L. (1965) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1965.tb20235.x · Cited by 1,438
Relapses and Progression of Disability in Multiple Sclerosis
Confavreux, C., Vukusic, S., Moreau, T., & Adeleine, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011163432001 · Cited by 1,309
Self-citationThe natural history of multiple sclerosis:a geographically based study
Cottrell, D. A., Kremenchutzky, M., Rice, G. P. A., Koopman, W. J., Hader, W., Baskerville, J., & Ebers, G. C. (1999) · Brain · doi:10.1093/brain/122.4.625 · Cited by 1,163
Confavreux, C. (2003) · Brain · doi:10.1093/brain/awg081 · Cited by 996
Self-citationUse of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS
Rudick, R. A., Fisher, E., Lee, J.-C., Simon, J., Jacobs, L., & the Multiple Sclerosis Collaborative Research Group (1999) · Neurology · doi:10.1212/wnl.53.8.1698 · Cited by 736
Losseff, N. A., Webb, S. L., O'Riordan, J. I., Page, R., Wang, L., Barker, G. J., Tofts, P. S., McDonald, W. I., Miller, D. H., & Thompson, A. J. (1996) · Brain · doi:10.1093/brain/119.3.701 · Cited by 643
Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up
Runmarker, B., & Andersen, O. (1993) · Brain · doi:10.1093/brain/116.1.117 · Cited by 568
Research works printed but not linked: 4
- Andersson PB, Waubant E, Gee L, Goodkin DE. Multiple sclerosis that is progressive from the time of onset. Clinical characteristics and progression of disability. Arch Neurol1999; 56: 1138–42. · doi:10.1001/archneur.56.9.1138
- Evangelou N, Esiri MM, Smith S, Palace J, Matthews PM. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol2000; 47: 391–5. · doi:10.1002/1531-8249(200003)47:3<391::aid-ana20>3.0.co;2-j
- Filippi M, Campi A, Martinelli V, Pereira C, Scotti G, Comi G. Transitional progressive multiple sclerosis: MRI and MTI findings. Acta Neurol Scand1995; 92: 178–82. · doi:10.1111/j.1600-0404.1995.tb01036.x
- Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol2000; 47: 707–17. · DOI
Cited by
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Multiple Sclerosis: An Immune or Neurodegenerative Disorder?
Trapp, B. D., & Nave, K.-A. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094313 · Cited by 1,724
Multiple Sclerosis: Current Knowledge and Future Outlook
Kamm, C. P., Uitdehaag, B. M., & Polman, C. H. (2014) · European Neurology · doi:10.1159/000360528 · Cited by 1,010
Treatment of Multiple Sclerosis: A Review
Hauser, S. L., & Cree, B. A. C. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.05.049 · Cited by 969
“2020;383(6):546–557 [PubMed: 32757523] 28.”
Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis
Howell, O. W., Reeves, C. A., Nicholas, R., Carassiti, D., Radotra, B., Gentleman, S. M., Serafini, B., Aloisi, F., Roncaroli, F., Magliozzi, R., et al. (2011) · Brain · doi:10.1093/brain/awr182 · Cited by 858
Primary-progressive multiple sclerosis
Miller, D. H., & Leary, S. M. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70243-0 · Cited by 818
The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration
Hauser, S. L., & Oksenberg, J. R. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.011 · Cited by 776
Jarius, S., Ruprecht, K., Wildemann, B., Kuempfel, T., Ringelstein, M., Geis, C., Kleiter, I., Kleinschnitz, C., Berthele, A., Brettschneider, J., et al. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-14 · Cited by 764
Frischer, J. M., Weigand, S. D., Guo, Y., Kale, N., Parisi, J. E., Pirko, I., Mandrekar, J., Bramow, S., Metz, I., Brück, W., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24497 · Cited by 728
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
Montalban, X., Gold, R., Thompson, A. J., Otero-Romero, S., Amato, M. P., Chandraratna, D., Clanet, M., Comi, G., Derfuss, T., Fazekas, F., et al. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458517751049 · Cited by 712
Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis
Zamboni, P., Galeotti, R., Menegatti, E., Malagoni, A. M., Tacconi, G., Dall'Ara, S., Bartolomei, I., & Salvi, F. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.157164 · Cited by 672
Natural History of Multiple Sclerosis with Childhood Onset
Renoux, C., Vukusic, S., Mikaeloff, Y., Edan, G., Clanet, M., Dubois, B., Debouverie, M., Brochet, B., Lebrun-Frenay, C., Pelletier, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067597 · Cited by 598
Self-citationJakimovski, D., Bittner, S., Zivadinov, R., Morrow, S. A., Benedict, R. H., Zipp, F., & Weinstock-Guttman, B. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01473-3 · Cited by 597
Evidence for a two-stage disability progression in multiple sclerosis
Leray, E., Yaouanq, J., Le Page, E., Coustans, M., Laplaud, D., Oger, J., & Edan, G. (2010) · Brain · doi:10.1093/brain/awq076 · Cited by 596
Rae-Grant, A., Day, G. S., Marrie, R. A., Rabinstein, A., Cree, B. A. C., Gronseth, G. S., Haboubi, M., Halper, J., Hosey, J. P., Jones, D. E., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005347 · Cited by 595
Progressive multiple sclerosis: from pathogenic mechanisms to treatment
Correale, J., Gaitán, M. I., Ysrraelit, M. C., & Fiol, M. P. (2016) · Brain · doi:10.1093/brain/aww258 · Cited by 573
Defining high, medium, and low impact prognostic factors for developing multiple sclerosis
Tintore, M., Rovira, À., Río, J., Otero-Romero, S., Arrambide, G., Tur, C., Comabella, M., Nos, C., Arévalo, M. J., Negrotto, L., et al. (2015) · Brain · doi:10.1093/brain/awv105 · Cited by 530
The epidemiology of multiple sclerosis
(2016) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-802973-2.00011-2 · Cited by 514
Miller, D. H., Chard, D. T., & Ciccarelli, O. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70274-5 · Cited by 507
Epidemiology of multiple sclerosis
Leray, E., Moreau, T., Fromont, A., & Edan, G. (2016) · Revue Neurologique · doi:10.1016/j.neurol.2015.10.006 · Cited by 478
The natural history of multiple sclerosis with childhood onset
Renoux, C., Vukusic, S., & Confavreux, C. (2008) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2008.04.009 · Cited by 450
Self-citationThe benefits of exercise training in multiple sclerosis
Motl, R. W., & Pilutti, L. A. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.136 · Cited by 394
Quantification of increased cellularity during inflammatory demyelination
Wang, Y., Wang, Q., Haldar, J. P., Yeh, F.-C., Xie, M., Sun, P., Tu, T.-W., Trinkaus, K., Klein, R. S., Cross, A. H., et al. (2011) · Brain · doi:10.1093/brain/awr307 · Cited by 384
Effect of Exercise Training on Walking Mobility in Multiple Sclerosis: A Meta-Analysis
Snook, E. M., & Motl, R. W. (2009) · Neurorehabilitation and Neural Repair · doi:10.1177/1545968308320641 · Cited by 374
Sankowski, R., Mader, S., & Valdés-Ferrer, S. I. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00028 · Cited by 351
The genetics of multiple sclerosis: SNPs to pathways to pathogenesis
Oksenberg, J. R., Baranzini, S. E., Sawcer, S., & Hauser, S. L. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2395 · Cited by 347
Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes
Ruano, L., Portaccio, E., Goretti, B., Niccolai, C., Severo, M., Patti, F., Cilia, S., Gallo, P., Grossi, P., Ghezzi, A., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458516674367 · Cited by 331
The slow death of the concept of schizophrenia and the painful birth of the psychosis spectrum
Guloksuz, S., & van Os, J. (2018) · Psychological Medicine · doi:10.1017/s0033291717001775 · Cited by 325
Demyelination versus remyelination in progressive multiple sclerosis
Bramow, S., Frischer, J. M., Lassmann, H., Koch-Henriksen, N., Lucchinetti, C. F., Sørensen, P. S., & Laursen, H. (2010) · Brain · doi:10.1093/brain/awq250 · Cited by 319
Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments
Weideman, A. M., Tapia-Maltos, M. A., Johnson, K., Greenwood, M., & Bielekova, B. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00577 · Cited by 310
Onset of secondary progressive phase and long-term evolution of multiple sclerosis
Scalfari, A., Neuhaus, A., Daumer, M., Muraro, P. A., & Ebers, G. C. (2014) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-304333 · Cited by 291
Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis
Rotstein, D., & Montalban, X. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0170-8 · Cited by 289
Mitroulis, I., Alexaki, V. I., Kourtzelis, I., Ziogas, A., Hajishengallis, G., & Chavakis, T. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.008 · Cited by 283
Remyelination therapies: a new direction and challenge in multiple sclerosis
Plemel, J. R., Liu, W.-Q., & Yong, V. W. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.115 · Cited by 281
Age and disability accumulation in multiple sclerosis
Scalfari, A., Neuhaus, A., Daumer, M., Ebers, G. C., & Muraro, P. A. (2011) · Neurology · doi:10.1212/wnl.0b013e318230a17d · Cited by 279
Relapses in multiple sclerosis are age- and time-dependent
Tremlett, H., Zhao, Y., Joseph, J., Devonshire, V, & Neurologists*, T. U. C. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.145805 · Cited by 277
Smouldering multiple sclerosis: the ‘real MS’
Giovannoni, G., Popescu, V., Wuerfel, J., Hellwig, K., Iacobaeus, E., Jensen, M. B., García-Domínguez, J. M., Sousa, L., De Rossi, N., Hupperts, R., et al. (2022) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211066751 · Cited by 271
Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis
Tutuncu, M., Tang, J., Zeid, N. A., Kale, N., Crusan, D. J., Atkinson, E. J., Siva, A., Pittock, S. J., Pirko, I., Keegan, B. M., et al. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458512451510 · Cited by 267
Environmental factors and their timing in adult-onset multiple sclerosis
Handel, A. E., Giovannoni, G., Ebers, G. C., & Ramagopalan, S. V. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.1 · Cited by 263
New perspectives in the natural history of multiple sclerosis
Tremlett, H., Zhao, Y., Rieckmann, P., & Hutchinson, M. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e3973f · Cited by 261
Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data
Eshaghi, A., Young, A. L., Wijeratne, P. A., Prados, F., Arnold, D. L., Narayanan, S., Guttmann, C. R. G., Barkhof, F., Alexander, D. C., Thompson, A. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22265-2 · Cited by 257
Internet intervention for increasing physical activity in persons with multiple sclerosis
Motl, R. W., Dlugonski, D., Wójcicki, T. R., McAuley, E., & Mohr, D. C. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458510383148 · Cited by 186
Hind, D., Cotter, J., Thake, A., Bradburn, M., Cooper, C., Isaac, C., & House, A. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-5 · Cited by 180
“Permanent physical and cognitive disabilities often follow later [1].”
BackgroundPrimary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome
Kantarci, O. H., Lebrun, C., Siva, A., Keegan, M. B., Azevedo, C. J., Inglese, M., Tintoré, M., Newton, B. D., Durand‐Dubief, F., Amato, M. P., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24564 · Cited by 167
Rawji, K. S., Young, A. M. H., Ghosh, T., Michaels, N. J., Mirzaei, R., Kappen, J., Kolehmainen, K. L., Alaeiilkhchi, N., Lozinski, B., Mishra, M. K., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02129-7 · Cited by 153
“In addition, as there is a strong correlation between increasing age with the onset of both primary and secondary progressive multiple sclerosis, it underscores the importance in establishing better animal models and discovering translational approaches to enhancing remyelination in the aging CNS [7, 15, 50].”
BackgroundInfluentialRasch analysis of the Fatigue Severity Scale in multiple sclerosis
Mills, R., Young, C., Nicholas, R., Pallant, J., & Tennant, A. (2009) · Multiple Sclerosis Journal · doi:10.1177/1352458508096215 · Cited by 114
The tension between early diagnosis and misdiagnosis of multiple sclerosis
Solomon, A. J., & Corboy, J. R. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.106 · Cited by 89
Tourdias, T., Roggerone, S., Filippi, M., Kanagaki, M., Rovaris, M., Miller, D. H., Petry, K. G., Brochet, B., Pruvo, J.-P., Radüe, E.-W., et al. (2012) · Radiology · doi:10.1148/radiol.12111416 · Cited by 85
Kallaur, A. P., Oliveira, S. R., Simão, A. N. C., Alfieri, D. F., Flauzino, T., Lopes, J., de Carvalho Jennings Pereira, W. L., de Meleck Proença, C., Borelli, S. D., Kaimen-Maciel, D. R., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-9846-x · Cited by 75
The Novo Group, Fernández, O., Fernández, V., Arbizu, T., Izquierdo, G., Bosca, I., Arroyo, R., García Merino, J. A., & de Ramón, E. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5560-1 · Cited by 69
Retinal and brain microglia in multiple sclerosis and neurodegeneration
Choi, S., Guo, L., & Cordeiro, M. F. (2021) · Cells · doi:10.3390/cells10061507 · Cited by 63
Böttcher, C., van der Poel, M., Fernández-Zapata, C., Schlickeiser, S., Leman, J. K. H., Hsiao, C.-C., Mizee, M. R., Adelia, Vincenten, M. C. J., Kunkel, D., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01010-8 · Cited by 58
Self-reported levels of education and disability progression in multiple sclerosis
D'hooghe, M. B., Haentjens, P., Van Remoortel, A., De Keyser, J., & Nagels, G. (2016) · Acta Neurologica Scandinavica · doi:10.1111/ane.12555 · Cited by 35
Hampton, D. W., Serio, A., Pryce, G., Al-Izki, S., Franklin, R. J., Giovannoni, G., Baker, D., & Chandran, S. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-84 · Cited by 34
Martin, N. A., Nawrocki, A., Molnar, V., Elkjaer, M. L., Thygesen, E. K., Palkovits, M., Acs, P., Sejbaek, T., Nielsen, H. H., Hegedus, Z., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0202530 · Cited by 29
Sex-dependent treatment of chronic EAE with partial MHC class II constructs
Benedek, G., Chaudhary, P., Meza-Romero, R., Calkins, E., Kent, G., Offner, H., Bourdette, D., & Vandenbark, A. A. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0873-y · Cited by 13
Neuroinflammation-on-a-chip for multiple sclerosis research: a narrative review
Berjaoui, C., Kachouh, C., Joumaa, S., Hussein Ghayyad, M., Abate Bekele, B., Ajirenike, R., Al Maaz, Z., Awde, S., Wojtara, M., Nazir, A., et al. (2024) · Annals of Medicine & Surgery · doi:10.1097/ms9.0000000000002231 · Cited by 4
Link of the mechanisms of action of glatiramer acetate to its long-term clinical data.
Moreau, T. (2009) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(09)70005-x · Cited by 2
“In the early stages, bursts of inflammatory activity are believed to be responsible for relapses, whereas in the later stages progressive neurodegeneration drives accumulation of irreversible disability independently of inflammation and relapses [10,11].”
Metadata
- Authors
- Confavreux, C., & Vukusic, S.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-01-16
- Volume
- 129
- Issue
- 3
- Pages
- 606-616
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2148563799
- Cited by
- 905
- References
- 52
- FWCI
- 21.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.